NRX Pharmaceuticals to Hold Special Meeting of Stockholders on March 21, 2024

TL;DR

NRX Pharmaceuticals is holding a special meeting on March 21, 2024, to vote on a proposed reverse stock split.

AI Summary

NRX Pharmaceuticals, Inc. (NRXPW) filed a Proxy Statement (DEF 14A) with the SEC on March 11, 2024. NRX Pharmaceuticals will hold a special meeting of stockholders on March 21, 2024, in a virtual-only format. The primary purpose of the meeting is to vote on an amendment to the company's Certificate of Incorporation to effect a reverse stock split. The reverse stock split ratio will be between 1-for-2 and 1-for-15, to be determined by the Board of Directors. The reverse stock split must be implemented prior to the one-year anniversary of its approval by stockholders. The Board of Directors unanimously recommends a vote of 'FOR' the reverse stock split proposal.

Why It Matters

For investors and stakeholders tracking NRX Pharmaceuticals, Inc., this filing contains several important signals. A reverse stock split is often implemented to increase the stock price, potentially making it more attractive to institutional investors and avoiding delisting from major exchanges. The outcome of this vote directly impacts the number of outstanding shares and the per-share price of NRX Pharmaceuticals' common stock.

Risk Assessment

Risk Level: low — NRX Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for a special meeting and does not contain new financial or operational data, thus posing minimal immediate risk.

Analyst Insight

Stockholders should carefully review the proxy statement to understand the implications of the proposed reverse stock split before voting.

Key Numbers

• March 21, 2024 — Special Meeting Date (Date of the Special Meeting of Stockholders.)
• 1-for-2 to 1-for-15 — Reverse Stock Split Ratio Range (The proposed range for the reverse stock split.)

Key Players & Entities

• NRX Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement.
• March 21, 2024 (date) — Date of the Special Meeting of Stockholders.
• March 11, 2024 (date) — Filing date of the proxy statement.
• 1-for-2 to 1-for-15 (dollar_amount) — Range for the proposed reverse stock split ratio.
• Big Rock Partners Acquisition Corp. (company) — Former name of NRX Pharmaceuticals, Inc.

FAQ

Risk Factors

• Reverse Stock Split Proposal [medium — financial]: The company is seeking stockholder approval for a reverse stock split to potentially increase its stock price and meet exchange listing requirements.

Industry Context

NRX Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on drug development and commercialization.

Regulatory Implications

The company is subject to SEC regulations regarding proxy solicitations and corporate governance, as evidenced by this DEF 14A filing.

What Investors Should Do

1. Review the full proxy statement for detailed information on the reverse stock split.
2. Consider the potential impact of a reverse stock split on share price and market perception.
3. Vote on the proposed amendment to the Certificate of Incorporation regarding the reverse stock split.

Key Dates

• 2024-03-21: Special Meeting of Stockholders — To vote on a proposed reverse stock split.
• 2024-03-11: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Glossary

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (This is the primary proposal being voted on at the special meeting, directly affecting share structure and price.)

Proxy Statement

A document filed with the SEC that provides information to shareholders about matters to be voted on at a company meeting. (This filing contains the details and rationale for the proposed reverse stock split and the board's recommendation.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting, distinct from regular periodic filings like 10-K or 10-Q, and does not provide comparative financial data.

Key Financial Figures

• $0.001 — outstanding shares of our common stock, $0.001 par value per share (the "Common Stock"
• $12,000 — expect to pay Continental approximately $12,000 for their services. What is "househol

Filing Documents

• tm2333863-2_def14a.htm (DEF 14A) — 228KB
• lg_nrx-4c.jpg (GRAPHIC) — 19KB
• px_24nrxspecialmeet01-bw.jpg (GRAPHIC) — 325KB
• px_24nrxspecialmeet02-bw.jpg (GRAPHIC) — 243KB
• 0001104659-24-033080.txt ( ) — 976KB

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 7 The Reverse Stock Split Proposal 9 Stockholder Proposals 18 Expenses and Solicitation 18 Householding of Proxy Materials 18 Other Matters 19 Annex A: Form of Reverse Stock Split Amendment A-1 i TABLE OF CONTENTS March 11, 2024 NRx Pharmaceuticals, Inc. 1201 Orange Street, Suite 600 Wilmington, DE 19801 (484) 254-6134 PROXY STATEMENT This proxy statement (the "Proxy Statement"), the attached Notice of Special Meeting of Stockholders (the "Notice") and the enclosed proxy card are being mailed to stockholders of record on or about March 11, 2024 and are furnished in connection with the solicitation of proxies by the Board of Directors (the "Board") of NRx Pharmaceuticals, Inc. (the "Company," "we," or "us") for use at our Special Meeting of Stockholders (the "Special Meeting"), to be held on March 21, 2024, at 11:00 a.m., Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/sm2024 , and at any adjournments or postponements thereof. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MARCH 21, 2024 This Proxy Statement is available for viewing, printing and downloading at www.nrxpharma.com 1 TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING What is a proxy? A proxy is a person you appoint to vote on your behalf. By using the methods discussed below, you will be appointing Stephen H. Willard as your proxy. The proxy will vote on your behalf, and will have the authority to appoint a substitute to act as proxy. If you are unable to attend the Special Meeting, please vote by proxy so that your shares may be voted. What is a proxy statement? A proxy statement is a document that regulations of the U.S. Securities and Exchange Commission (the "SEC") require that we give to you when we ask you to sign a proxy card to vote your share

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The following table sets forth information with respect to the beneficial ownership of our common stock, as of March 7, 2024, by: each person who is the beneficial owner of more than 5% of the outstanding shares of our common stock; each of our Named Executive Officers and directors; and all of our executive officers and directors as a group. Beneficial ownership for the purposes of the following table is determined in accordance with the rules and regulations of the SEC. A person is a "beneficial owner" of a security if that person has or shares "voting power," which includes the power to vote or to direct the voting of the security, or "investment power," which includes the power to dispose of or to direct the disposition of the security or has the right to acquire such powers within 60 days. Accordingly, we have included all shares of common stock issuable to such person upon the exercise of warrants or options currently exercisable or exercisable within 60 days of March 7, 2024. We did not deem such shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned common stock and preferred stock. Except as indicated in the footnotes to the table, each of the stockholders listed below has sole voting and investment power with respect to the shares of Common Stock owned by such stockholders. Unless otherwise noted, the address of each beneficial owner is c/o NRx Pharmaceuticals, Inc., 1201 North Market Street, Suite 111, Wilmington, DE 19801. The beneficial ownership of our common stock is based on 92,425,580 shares of common stock issued and outstanding as of March 7, 2024. Name

View Full Filing

View this DEF 14A filing on SEC EDGAR